Dun Niu

Dun Niu

Auto-generated profile, based on publicly available information

Dun Niu

Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
DNDun Niu
Dun Niu
YWYaran Wu
Yaran Wu
JLJiqin Lian
Jiqin Lian
CircRNAs are a class of single-stranded RNAs with covalently linked head-to-tail topology. In the decades since its initial discovery, their biogenesis, regulation, and function have rapidly disclosed, permitting a better understanding and adoption of them as new tools for medical applications. With the development of biotechnology and molecular medicine, artificial circRNAs have been engineered as a novel class of vaccines for disease treatment and prevention. Unlike the linear mRNA vaccine which applications were limited by its instability, inefficiency, and innate immunogenicity, circRNA vaccine which incorporate internal ribosome entry sites (IRESs) and open reading frame (ORF) provides an improved approach to RNA-based vaccination with safety, stability, simplicity of manufacture, and scalability. However, circRNA vaccines are at an early stage, and their optimization, delivery and applications require further development and evaluation. In this review, we comprehensively describe circRNA vaccine, including their history and superiority. We also summarize and discuss the current methodological research for circRNA vaccine preparation, including their design, synthesis, and purification. Finally, we highlight the delivery options of circRNA vaccine and its potential applications in diseases treatment and prevention. Considering their unique high stability, low immunogenicity, protein/peptide-coding capacity and special closed-loop construction, circRNA vaccine, and circRNA-based therapeutic platforms may have superior application prospects in a broad range of diseases.

1 November 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
DNDun Niu
Dun Niu
TLTing Luo
Ting Luo
HWHanbin Wang
Hanbin Wang
YXYiniu Xia
Yiniu Xia
ZXZhizhong Xie
Zhizhong Xie

4 February 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
DNDun Niu
Dun Niu
YWYiwen Wu
Yiwen Wu
ZLZiyao Lei
Ziyao Lei
MZMing Zhang
Ming Zhang
ZXZhizhong Xie
Zhizhong Xie
STShengsong Tang
Shengsong Tang

8 March 2024 in Autophagy
Verified
Journal Article
Closed access
YWYaran Wu
Yaran Wu
YCYang Chen
Yang Chen
XYXiaojing Yan
Xiaojing Yan
XDXufang Dai
Xufang Dai
YLYaling Liao
Yaling Liao
JLJiqin Lian
Jiqin Lian

17 June 2021 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
DNDun Niu
Dun Niu
LLLanfang Li
Lanfang Li
ZXZhizhong Xie
Zhizhong Xie
Chloride channel 3 (ClC-3), a Cl−/H+ antiporter, has been well established as a member of volume-regulated chloride channels (VRCCs). ClC-3 may be a crucial mediator for activating inflammation-associated signaling pathways by regulating protein phosphorylation. A growing number of studies have indicated that ClC-3 overexpression plays a crucial role in mediating increased plasma low-density lipoprotein levels, vascular endothelium dysfunction, pro-inflammatory activation of macrophages, hyper-proliferation and hyper-migration of vascular smooth muscle cells (VSMCs), as well as oxidative stress and foam cell formation, which are the main factors responsible for atherosclerotic plaque formation in the arterial wall. In the present review, we summarize the molecular structures and classical functions of ClC-3. We further discuss its emerging role in the atherosclerotic process. In conclusion, we explore the potential role of ClC-3 as a therapeutic target for atherosclerosis.

31 July 2025 in Cell Biology International
Verified
Journal Article
Closed access
DNDun Niu
Dun Niu
YXYiniu Xia
Yiniu Xia
XQXingyu Qin
Xingyu Qin
MZMing Zhang
Ming Zhang
SPSichun Pan
Sichun Pan
ZXZhizhong Xie
Zhizhong Xie